Purpose: Our previous studies have identified isoginkgetin as an inducer of autophagic cell death in hepatocellular carcinoma. We set out to analyze how isoginkgetin regulates the genome-wide enhancer activity in HepG2 cells. Methods: ChIP-seq for H3K27ac was performed in HepG2 followed by treatment with 20 μM isoginkgetin for 24 h. Conclusions: Isoginkgetin treatment reduces the expression of glucose transporters and inhibts SLC2A1 enhancer activity in HepG2 cells. Overall design: ChIP-seq was performed with two repetitions in HepG2 cells followed by treatment with20 μM Isoginkgetin for 24 h. The genome-wide enhancer activity was studied by H3K27ac ChIP sequencing.